Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus High-Dose Ascorbate in Sarcoma
NCT04877587Phase 1Withdrawn
- Start
- Jan 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ascorbic acid in soft tissue sarcoma (STS) and bone sarcoma. Primary endpoints: Adverse Events as defined by CTCAE version 5.0 and Overall Response Rate at 2 years. Planned start Jan 2023; status: withdrawn.
02
Drugs
ascorbic acid
03
Conditions
soft tissue sarcoma (STS)bone sarcoma
Beyond the preview
Go deeper on NCT04877587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877587.